Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265051 | 0.86 | CYP3A4 (0.32) | GPBAR1CYP3A4MAPTMAPK1PSEN1 | |
| SCHEMBL5670517 | 0.83 | KCNH2 (0.38) | GPBAR1TAS2R14CYP3A4MAPTMAPK1 | |
| SCHEMBL1899458 | 0.77 | CETP (0.46) | — | |
| SCHEMBL5148374 | 0.77 | SERPINE1 (0.39) | CYP3A4MAPTMAPK1RXRARXRG | |
| SCHEMBL2264234 | 0.74 | CYP3A4 (0.34) | GPBAR1CYP3A4MAPTMAPK1 | |
| SCHEMBL2265549 | 0.74 | CYP3A4 (0.33) | GPBAR1CYP3A4MAPTMAPK1NR1H2 | |
| SCHEMBL2261529 | 0.72 | CYP3A4 (0.40) | GPBAR1CYP3A4MAPTMAPK1NR1H2 | |
| SCHEMBL2269142 | 0.71 | CYP3A4 (0.41) | CYP3A4MAPTMAPK1 | |
| SCHEMBL5671071 | 0.70 | NR1H2 (0.41) | CYP3A4MAPTMAPK1RXRARXRG | |
| SCHEMBL5669136 | 0.69 | CETP (0.34) | GPBAR1CYP3A4MAPTMAPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | GPBAR1 329/4885TAS2R14 4585/4885CYP3A4 1980/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | GPBAR1 329/4885TAS2R14 4585/4885CYP3A4 1980/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | GPBAR1 308/4885TAS2R14 2242/4885CYP3A4 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.